Image source: The Motley Fool. DATE Wednesday, May 21, 2025, at 8:30 a.m. EDT Read More: Earn up to $845 cash back this year just by changing how you pay at Costco! Learn more here. CALL ...

YAVNE, Israel, May 21, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for ...

YAVNE, Israel - MediWound Ltd. (NASDAQ:MDWD), a $201.56 million market cap company specializing in enzymatic therapeutics for tissue repair, announced findings from a post hoc analysis published in ...

MediWound publishes analysis showing EscharEx® outperforms SANTYL® in treating venous leg ulcers, highlighting faster debridement and wound healing.

--MediWound Ltd., a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the publication of a peer-reviewed post hoc analysis in Wounds. Cyaandi Dove, DPM, of ...

This announcement is based on a press release statement and provides insights into the potential clinical benefits of EscharEx in comparison to SANTYL, offering a new therapeutic option for ...

Post hoc analysis published in the peer-reviewed journal Wounds highlights EscharEx®’s superior clinical performance and comparable safety profile to SANTYL®YAVNE, Israel, May 13, 2025 (GLOBE ...

Post hoc analysis published in the peer-reviewed journal Wounds highlights EscharEx®’s superior clinical performance and comparable safety profile to SANTYL®YAVNE, Israel, May 13, 2025 (GLOBE NEWSWIRE ...

The analysis is based on data from the Company's Phase II ChronEx clinical trial in patients with venous leg ulcers (VLUs) evaluating the efficacy and safety of EscharEx ® compared with collagenase ...

Smith+Nephew First Quarter 2025 Trading Update Good start to 2025, reinforcing confidence in full year outlook 30 April 2025 Smith+Nephew (LSE:SN, NYSE:SNN) trading update for the first quarter ...

Completed a head-to-head comparative analysis of EscharEx vs. SANTYL ® from a Phase II trial, demonstrating EscharEx's superiority in key clinical outcomes.

The Business Research Company's Santyl Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034 Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase ...